Compagnie Lombard Odier SCmA Sells 17,275 Shares of IQVIA Holdings Inc. $IQV

Compagnie Lombard Odier SCmA lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 15.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 97,057 shares of the medical research company’s stock after selling 17,275 shares during the period. Compagnie Lombard Odier SCmA’s holdings in IQVIA were worth $18,435,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc boosted its holdings in shares of IQVIA by 6.3% during the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after buying an additional 53 shares in the last quarter. Private Trust Co. NA lifted its position in IQVIA by 12.5% during the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 67 shares during the period. CVA Family Office LLC boosted its stake in IQVIA by 11.6% during the third quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock worth $124,000 after acquiring an additional 68 shares in the last quarter. E Fund Management Co. Ltd. grew its holdings in IQVIA by 3.7% in the second quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock worth $331,000 after purchasing an additional 74 shares during the period. Finally, UMB Bank n.a. increased its stake in shares of IQVIA by 11.0% during the third quarter. UMB Bank n.a. now owns 749 shares of the medical research company’s stock valued at $142,000 after purchasing an additional 74 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IQV. JPMorgan Chase & Co. cut their price target on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday. Citigroup lowered their price target on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday. Evercore ISI reissued an “outperform” rating on shares of IQVIA in a research report on Thursday. Finally, Morgan Stanley lifted their target price on shares of IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $239.87.

IQVIA Price Performance

NYSE IQV opened at $192.58 on Tuesday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75. The company has a market capitalization of $32.80 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 1.90 and a beta of 1.37. The stock has a 50-day moving average of $227.31 and a 200 day moving average of $209.81. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. During the same period in the previous year, the business posted $3.12 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.